Takeda’s Adcetris gets EU green light
Takeda has announced that the European Commission has extended the current marketing authorisation of Adcetris to include treatment of adults with previously untreated CD30+ Stage IV Hodgkin lymphoma.
Read More
Tag: Stage IV Hodgkin lymphoma
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
